[CLSTR]
< Back to situation

[REVISION HISTORY]

Bryan Johnson's iPSC 'baby‑Bryan' clone

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-07-27 14:20 UTC → 2026-07-28 19:43 UTC · added removed

On 22 July 2026 Bryan Johnson announced that scientists had reprogrammed his blood‑derived cells into induced pluripotent stem cells (iPSCs) and cultured a petri‑dish “baby‑Bryan.” He framed the line creation of an iPSC‑derived “baby‑Bryan” line, describing it as a personal blood donor, donor and a testing platform for anti‑aging drugs and a potential source of transplantable tissue, linking drug testing. He linked the work to his a recent autoimmune gastritis diagnosis of autoimmune gastritis, noting elevated anti‑parietal cell antibodies and early gastric atrophy as part of his multi‑million‑dollar Blueprint longevity regimen, which already includes blood transfusions from his teenage son. The claim reignited debate: supporters highlighted regenerative‑medicine promise, while critics warned that “clone” is misleading, that iPSC reprogramming yields embryonic‑like cells, not a separate human, and emphasized safety, efficiency and tumor‑formation concerns. Geneticists reiterated that human cloning remains prohibited. Johnson followed up reiterated on 24 July, reiterating July that the line is a “newborn clone” that could serve as his own donor and organ source, and again cited his gastritis diagnosis as motivation. A further post on 27 July added provided technical detail, stating the reprogramming uses detail about using the Yamanaka factors and factors, suggesting that genetically identical cells might reduce organ‑rejection rejection risk. In a concurrent statement the same day he disclosed the gastritis findings in more detail and reaffirmed the newborn‑clone claim, prompting additional expert skepticism that the approach could ever yield a viable human clone for organ generation. The announcement announcements attracted international media attention, including coverage in Portugal, and prompted renewed expert cautions that the work remains confined to the laboratory laboratory, that iPSC reprogramming yields embryonic‑like cells rather than a separate human, and that therapeutic expectations remain speculative.

Versions

  1. 2026-07-28 19:43 UTC Bryan Johnson's iPSC 'baby‑Bryan' clone
  2. 2026-07-27 14:20 UTC Bryan Johnson's iPSC 'baby‑Bryan' clone

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.